Clinical Trial Update: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes a Phase 2/3 study evaluating tideglusib for congenital or childhood-onset myotonic dystrophy that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Tideglusib (tideglusib)

Snippet

Sponsor: AMO Pharma Limited | Conditions: Congenital Myotonic Dystrophy | Phase 2, Phase 3 | Status: RECRUITING